BioMarin Now Turns To Commercializing Its Gene Therapy, Roct

As BioMarin turns to commercialization of Roctavian, we will likely hear more about how warranties could help gene therapies overcome payer reimbursement hurdles.

Related Keywords

Germany , France , Italy , Jean Jacques Bienaim , Jeff Ajer , Centers For Medicare , Veterans Affairs , Institute For Clinical , Medicaid Services , National Association Of Statutory Health Insurance Funds , Economic Review , National Association , Statutory Health Insurance Funds , Jacques Bienaim , Octaviant Financial ,